TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Growth velocity of the right lower leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular intramyocardial triglyceride/water ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: area under the curve of plasma CHF 5074 levels from 0 to 96 hours (AUC 0-96)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak CHF 5074 plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip flexion and knee extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bipolar Inventory of Symptoms Scale (BISS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anti Factor Xa level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in Hamilton Rating Scale for Depression (HAM-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sperm Concentration Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of exacerbations for asthma or COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of mirtazapine for treatment of schizophrenia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum measured concentration of the analyte in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liking of oral nutritional supplements
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients with benign lymphadenopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Acquisition of SARS-CoV 2 Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time to reversal of diabetic ketoacidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total crystalline insulin consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in fear of performance/public speaking symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients receiving Radium-223 injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in corneal CRF and CH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Return of Bowel Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnosis of undiagnosed pleural effusion cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip Sway Change From Baseline to 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle Sway Change From Baseline to 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of Mass (COM) Sway Change Baseline to 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compartmental FeNO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calculated compartmental airway pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled Breath Condensate (EBC) pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients reaching full clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GFR loss of 15 ml/min or higher from baseline GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Knowledge about COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perception about COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude towards COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Virological profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological profile with blood level for markers of inflammation (cytokine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biochemical profile by blood dosage of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting exchange ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain experienced by child during pulpal treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Oral Mucosal Exfoliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite Clinical Success (CCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Disease Activity Score 28 - C-Reactive Protein (DAS28-CRP) Score < 3.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Positive Serum Level of Matrix Metalloprotease-3 (MMP-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Health Assessment Questionnaire (HAQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: uptake distribution of the HER2-binding imaging agent [68Ga]ABY-025
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Number of Weekly Cannabis Use Sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Correct administration and interpretation of RDTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative Image assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Assessment from Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of treatment emergent adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least a 2-Grade Decrease From Baseline on CEA and SSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Opiate craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with negative findings from FDG-PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin urinary excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overlap of epileptogenic zone with brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants That Respond to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of rPA vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Reporting Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LV EDV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of cocaine in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Yale Preoperative Anxiety Score (mYPAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the curve (AUC) of plasma concentration vs. time of total tocopherols and tocotrienols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the curve (AUC) of plasma concentration vs. time of total ferulic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the curve (AUC) of plasma concentration vs. time of total gamma-oryzanol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Evaluation: Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Range of Motion Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Shoulder Function and Disability Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Dementia Rating scale (CDR) sum of boxes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objective success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD symptoms as recorded by the Clinicians Administered PTSD Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response measured by CTL frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean percentage of change of alveolar bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival at 7 days post randomization with resolution of fever and resolution of hypotension
Endpoint domain: Mortality/survival
Primary endpoint: 30-day all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Elevated ampicillin serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of lipid status parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tibial cortical density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically significant laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinically significant electrocardiogram (ECG) abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects achieving transfusion independence for at least 12 consecutive months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to neutrophil and platelet engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Pain Score on FLACC Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of symptomatic or complicated GI events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time of functional recovery from surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death due to progressive neurologic disease
Endpoint domain: Mortality/survival
Primary endpoint: Oxygen Saturation (SpO2) Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants completing neoadjuvant atezolizumab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hospitalizations for Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urgent Visits for Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in keratotic nodular size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Spontaneous immune responses of T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Percent of Dose Recovered in Urine and Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Immune Reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of biopsies collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Infant/Toddler Sensory Profile (ITSP)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Infant Traumatic Stress Questionnaire (ITSQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Child Traumatic Stress Questionnaire (CTSQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PSI-SF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants without clinical relapse
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Events (Safety)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of postoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or Absence of Cell Free Fetal DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Use of Midazolam Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose Use of Propofol Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose Use of Sufentanil Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Who Are Progression Free at One Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Acceptance Rate of PrEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of Refusal Rate of PrEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of Side Effects/Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Nonfatal Acute Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular End-systolic Volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heme oxygenase-1 protein expression in circulating monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete Remission of Diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical benefit rate (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with combined (virological and biochemical) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of Participants With Grade 2 Rash or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: 3D kinematic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unit length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Area under the concentration-time curve (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal phase half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wear of Enamel Antagonist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Healthcare Service Usage for Genital Warts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Healthcare Service Usage for Preneoplastic Cervical Lesions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: time of drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prolapse symptom score (POP-SS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Level of Immunoglobulin (Ig) A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The Level of Immunoglobulin (Ig) G
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The Level of Immunoglobulin (Ig) M
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The Level of Interleukin (IL)-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The Level of Interleukin (IL)-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of symptom improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin response during hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cognitive function as assessed by PPVT-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language abilities as assessed by CELF-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function as assessed by Woodcock-Johnson Test of Achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function as assessed by Leiter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiologic eradication of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline physical performance measured by SPPB (score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Reduction in Ventricular Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: platelet mitochondria cytochrome oxidase (COX) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change in Average Score on mHAQ Section 1
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percent Change in Average Score on mHAQ Section 1
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent Change in Average Score on mHAQ Section 1
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: complete relief of dyspeptic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Reported Emotion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Reported Social Reinforcement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Predictive value of early serum trough concentrations of guselkumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of early anti-drug antibodies of guselkumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of the therapeutic window of guselkumab in psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of testican-1 and ubiquitin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Identification of Streptococcus Group B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the 89-12 IgA Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Serum Anti-rotavirus IgA Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in near working distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in refractive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success or failure at 18 months follow-up visit
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: aortic disease-related death
Endpoint domain: Mortality/survival
Primary endpoint: aortic dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: renal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Eating Behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Subjective Illness Representations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing